Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells.
Highly purified peripheral blood monocytes from normal human donors were activated in vitro by incubation with liposomes containing immunomodulators such as recombinant human gamma interferon, human lymphokines, or muramyl dipeptide. The ability of liposomes containing immunomodulators to activate monocytes to a cytotoxic state capable of discriminating between virus-infected and uninfected cells was shown by activated monocytes recognizing and destroying herpes simplex virus type 2-infected cells while leaving uninfected cells unharmed .
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use; D008081:Liposomes / Q000008:administration & dosage; D008222:Lymphokines / Q000627:therapeutic use; D016215:Macrophage-Activating Factors; D009000:Monocytes / Q000187:drug effects* / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy; D010714:Phosphatidylethanolamines / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D008081:Liposomes; D008222:Lymphokines; D016215:Macrophage-Activating Factors; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D007371:Interferon-gamma